SG11201908567UA - Modified cyclic dinucleotide compounds - Google Patents
Modified cyclic dinucleotide compoundsInfo
- Publication number
- SG11201908567UA SG11201908567UA SG11201908567UA SG11201908567UA SG 11201908567U A SG11201908567U A SG 11201908567UA SG 11201908567U A SG11201908567U A SG 11201908567UA SG 11201908567U A SG11201908567U A SG 11201908567UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- ingelheim
- rhein
- gmbh
- boehringer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Financial Or Insurance-Related Operations Such As Payment And Settlement (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17162392 | 2017-03-22 | ||
| PCT/EP2018/056656 WO2018172206A1 (en) | 2017-03-22 | 2018-03-16 | Modified cyclic dinucleotide compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201908567UA true SG11201908567UA (en) | 2019-10-30 |
Family
ID=58412904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908567U SG11201908567UA (en) | 2017-03-22 | 2018-03-16 | Modified cyclic dinucleotide compounds |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10392419B2 (es) |
| EP (1) | EP3601313B1 (es) |
| JP (2) | JP6742534B2 (es) |
| KR (1) | KR20190130612A (es) |
| CN (1) | CN110382515B (es) |
| AR (1) | AR111247A1 (es) |
| AU (1) | AU2018239468A1 (es) |
| BR (1) | BR112019017812A2 (es) |
| CA (1) | CA3056008A1 (es) |
| CL (1) | CL2019002590A1 (es) |
| CO (1) | CO2019010023A2 (es) |
| EA (1) | EA201992209A1 (es) |
| IL (1) | IL268799A (es) |
| JO (1) | JOP20190218A1 (es) |
| MX (1) | MX2019011281A (es) |
| PE (1) | PE20191556A1 (es) |
| PH (1) | PH12019502155A1 (es) |
| SG (1) | SG11201908567UA (es) |
| TW (1) | TW201842919A (es) |
| WO (1) | WO2018172206A1 (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018068748B1 (pt) | 2016-03-18 | 2024-01-16 | The Board Of Regents Of The University Of Texas System | Composto dinucleotídeo cíclico, composição farmacêutica, e, uso de um composto |
| KR20230133947A (ko) * | 2016-06-24 | 2023-09-19 | 바이오젠 엠에이 인코포레이티드 | 캡핑 단계 없이 티올화된 올리고뉴클레오타이드의 합성 |
| EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
| JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
| JOP20190218A1 (ar) * | 2017-03-22 | 2019-09-22 | Boehringer Ingelheim Int | مركبات ثنائية النيوكليوتيدات حلقية معدلة |
| CN111566119A (zh) | 2017-11-10 | 2020-08-21 | 武田药品工业有限公司 | Sting调节剂化合物以及制备和使用方法 |
| CA3084582A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| WO2019123340A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| US20210024567A1 (en) * | 2018-03-27 | 2021-01-28 | Boehringer Ingelheim International Gmbh | Modified cyclic dinucleotide compounds |
| CA3093888A1 (en) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| US20220024964A1 (en) * | 2018-12-07 | 2022-01-27 | Merck Sharp & Dohme Corp. | Cyclic Di-Nucleotide Compounds as STING Agonists |
| EP3891166A4 (en) * | 2018-12-07 | 2022-08-24 | Merck Sharp & Dohme Corp. | CYCLIC DI-NUCLEOTIDE COMPOUNDS USED AS STING AGONISTS |
| WO2020117625A1 (en) * | 2018-12-07 | 2020-06-11 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
| WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
| CA3137119A1 (en) | 2019-05-09 | 2020-11-12 | Aligos Therapeutics, Inc. | Modified cyclic dinucleoside compounds as sting modulators |
| JP2022532192A (ja) | 2019-05-10 | 2022-07-13 | 武田薬品工業株式会社 | 抗体薬物複合体 |
| JP2022538690A (ja) | 2019-07-05 | 2022-09-05 | タンボ・インコーポレイテッド | トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用 |
| CA3157192A1 (en) * | 2019-10-07 | 2021-04-15 | The General Hospital Corporation | Compositions and methods for pulmonary surfactant-biomimetic nanoparticles |
| EP4134098A4 (en) | 2020-04-10 | 2024-05-15 | Ono Pharmaceutical Co | CANCER THERAPY METHODS |
| EP4192506A1 (en) | 2020-08-07 | 2023-06-14 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| JP2023545178A (ja) | 2020-10-14 | 2023-10-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｔｉｎｇアゴニストと、細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む複合体との組合せ |
| PE20231947A1 (es) | 2020-11-09 | 2023-12-05 | Takeda Pharmaceuticals Co | Conjugados de anticuerpo y farmaco |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2560058C (en) | 2004-03-15 | 2011-10-18 | David K.R. Karaolis | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis |
| US7592326B2 (en) | 2004-03-15 | 2009-09-22 | Karaolis David K R | Method for stimulating the immune, inflammatory or neuroprotective response |
| EA201170375A1 (ru) | 2008-08-25 | 2012-03-30 | Эмплиммьюн, Инк. | Антагонисты pd-1 и способы их применения |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| JP6023706B2 (ja) | 2010-07-09 | 2016-11-09 | アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． | Ｃｄ２７に対するアゴニスト抗体 |
| SG10201704611WA (en) * | 2012-12-13 | 2017-07-28 | Aduro Biotech Inc | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| ES2678194T3 (es) | 2012-12-19 | 2018-08-09 | Board Of Regents, The University Of Texas System | Determinación farmacéutica de una vía de señalización de dinucleótido cíclico de mamífero |
| ES2822584T3 (es) | 2013-05-03 | 2021-05-04 | Univ California | Inducción de dinucleótidos cíclicos del interferón tipo I |
| SG11201508273RA (en) | 2013-05-18 | 2015-12-30 | Aduro Biotech Inc | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
| US10176292B2 (en) | 2013-07-31 | 2019-01-08 | Memorial Sloan-Kettering Cancer Center | STING crystals and modulators |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| TWI777174B (zh) | 2014-03-14 | 2022-09-11 | 瑞士商諾華公司 | 針對lag-3之抗體分子及其用途 |
| EA029856B9 (ru) | 2014-06-04 | 2018-08-31 | Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Циклические динуклеотиды в качестве модуляторов стимулятора генов интерферона (sting) |
| PT3233882T (pt) | 2014-12-16 | 2020-01-21 | Kayla Therapeutics | Dinucleótidos cíclicos fluorados para a indução de citocinas |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| PE20171448A1 (es) * | 2015-03-10 | 2017-10-02 | Aduro Biotech Inc | Composiciones y metodos para activar la senalizacion dependiente del estimulador del gen de interferon |
| WO2017027645A1 (en) | 2015-08-13 | 2017-02-16 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
| EP3507367A4 (en) * | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
| JOP20190218A1 (ar) * | 2017-03-22 | 2019-09-22 | Boehringer Ingelheim Int | مركبات ثنائية النيوكليوتيدات حلقية معدلة |
-
2017
- 2017-06-16 JO JOP/2019/0218A patent/JOP20190218A1/ar unknown
-
2018
- 2018-03-16 BR BR112019017812-0A patent/BR112019017812A2/pt not_active Application Discontinuation
- 2018-03-16 KR KR1020197030982A patent/KR20190130612A/ko not_active Application Discontinuation
- 2018-03-16 MX MX2019011281A patent/MX2019011281A/es unknown
- 2018-03-16 EP EP18710069.8A patent/EP3601313B1/en active Active
- 2018-03-16 WO PCT/EP2018/056656 patent/WO2018172206A1/en unknown
- 2018-03-16 CA CA3056008A patent/CA3056008A1/en not_active Abandoned
- 2018-03-16 SG SG11201908567U patent/SG11201908567UA/en unknown
- 2018-03-16 EA EA201992209A patent/EA201992209A1/ru unknown
- 2018-03-16 AU AU2018239468A patent/AU2018239468A1/en not_active Abandoned
- 2018-03-16 PE PE2019001891A patent/PE20191556A1/es unknown
- 2018-03-16 CN CN201880016136.8A patent/CN110382515B/zh active Active
- 2018-03-16 JP JP2019552098A patent/JP6742534B2/ja active Active
- 2018-03-20 US US15/925,887 patent/US10392419B2/en active Active
- 2018-03-21 AR ARP180100663A patent/AR111247A1/es unknown
- 2018-03-21 TW TW107109571A patent/TW201842919A/zh unknown
-
2019
- 2019-08-20 IL IL26879919A patent/IL268799A/en unknown
- 2019-09-11 CL CL2019002590A patent/CL2019002590A1/es unknown
- 2019-09-16 CO CONC2019/0010023A patent/CO2019010023A2/es unknown
- 2019-09-20 PH PH12019502155A patent/PH12019502155A1/en unknown
-
2020
- 2020-07-28 JP JP2020127120A patent/JP2020203887A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| IL268799A (en) | 2019-10-31 |
| EA201992209A1 (ru) | 2020-03-16 |
| CA3056008A1 (en) | 2018-09-27 |
| US20180273578A1 (en) | 2018-09-27 |
| JP6742534B2 (ja) | 2020-08-19 |
| EP3601313B1 (en) | 2021-03-10 |
| AR111247A1 (es) | 2019-06-19 |
| MX2019011281A (es) | 2019-11-01 |
| AU2018239468A1 (en) | 2019-09-12 |
| US10392419B2 (en) | 2019-08-27 |
| PH12019502155A1 (en) | 2020-07-06 |
| CL2019002590A1 (es) | 2020-01-24 |
| BR112019017812A2 (pt) | 2020-03-31 |
| JOP20190218A1 (ar) | 2019-09-22 |
| KR20190130612A (ko) | 2019-11-22 |
| CO2019010023A2 (es) | 2019-09-30 |
| WO2018172206A1 (en) | 2018-09-27 |
| CN110382515B (zh) | 2023-03-03 |
| JP2020203887A (ja) | 2020-12-24 |
| TW201842919A (zh) | 2018-12-16 |
| PE20191556A1 (es) | 2019-10-24 |
| EP3601313A1 (en) | 2020-02-05 |
| CN110382515A (zh) | 2019-10-25 |
| JP2020514389A (ja) | 2020-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201805888SA (en) | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer | |
| SG11201906763RA (en) | Pyrrolo [1,2-b] pyridazine derivatives | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201907032RA (en) | Amino pyrimidine compounds useful as ssao inhibitors | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201806342SA (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
| SG11201901347UA (en) | Compositions and methods for cancer immunotherapy | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201900361RA (en) | Methods of treating prostate cancer | |
| SG11201906682YA (en) | Glucagon receptor binding proteins and methods of use thereof | |
| SG11202000494UA (en) | Drug delivery composition | |
| SG11201810801QA (en) | Brain delivery protein | |
| SG11201909840TA (en) | Treatment of epithelial cysts by intracystic injection of antineoplastic particles |